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Aided by the 
 
Plasmodium falciparum
 
 genome project,
recent discoveries regarding the molecular basis of
malaria pathogenesis have led to a better under-
standing of the interactions between host and para-
site. Although vaccines that prevent infection by
malaria parasites remain only hopes for the future,
there are now more immediate prospects for vaccines
that protect against specific disease syndromes. Here,
we discuss the latest advances in the development of a
vaccine that specifically targets pregnancy-associated
malaria (PAM).
 
Pregnancy-associated Malaria.
 
It has long been observed
that there is an increase in the severity of malaria during
pregnancy, resulting in such negative outcomes as maternal
anemia and reduction in birth weight, which in turn lead
to increases in maternal and infant mortality (1). It has been
estimated that as many as 300,000 fetal and infant deaths
and 2,500 maternal deaths may be attributable to increased
malaria susceptibility during pregnancy (2). The increased
vulnerability of both mother and developing child to ma-
laria results from the specific adherence and accumulation
of parasite-infected erythrocytes within the placenta and a
potentially important localized immune response (3, 4).
Unlike other sequestration sites, inflammatory cells are a
prominent component of infected placentas (1). In particu-
lar, monocytes are heavily recruited to the infected placenta
by unknown processes and may have both immunoprotec-
tive and immunopathological activities. In their extreme,
monocytic infiltrates have been associated with a “massive
chronic intervillositis” or placental inflammation (1).
More generally, malaria pigment-containing placental mono-
cytes have been linked to maternal anemia and low birth
weight, suggesting these may contribute to their develop-
ment (1, 5).
Over the last decade, a new model has emerged to ex-
plain PAM based on the distinctive adhesion properties of
infected placental erythrocytes (Fig. 1), providing the first
hint that a precise vaccine targeting this syndrome might be
possible. Specifically, it was shown that placental chon-
droitin sulfate A (CSA) serves as a receptor for infected
erythrocyte binding (6, 7). Infected RBCs isolated from
placenta bind CSA, hyaluronic acid, and possibly other re-
ceptors, but not the primary receptor that mediates infected
RBC binding to the microvasculature, CD36. In infected
pregnant women, this results in the selection of a subpopu-
lation of parasites expressing molecules that mediate adhe-
sion of infected RBCs to CSA. From the perspective of
vaccine development, there were two encouraging obser-
vations concerning this subpopulation of parasite-infected
cells. First, there is a reduction in susceptibility to PAM in
multigravid women, indicating that women can develop
immunity to PAM after infection (1, 3, 4). Second, women
develop broadly reactive antibodies to infected cells isolated
from placentas (8), suggesting that it may be possible to
stimulate a protective immune response that prevents PAM.
These observations stimulated a search for the molecules
on placental adherent-infected RBCs that are recognized by
antibodies—the putative adhesion receptors. A leading can-
didate for the placental adhesion receptor is the parasite vari-
ant surface antigen responsible for cytoadhesive activity and
encoded by 
 
var
 
 genes (9). The multicopy 
 
var
 
 gene family was
shown previously to encode multiple forms of the 
 
P. falci-
parum
 
 erythrocyte membrane protein 1 (PfEMP1) (10). In-
dividual parasites express a single 
 
var
 
 gene, exporting the en-
coded PfEMP1 molecule to the surface of the infected RBC
where it acts as the primary cytoadherence determinant.
This adhesive property leads to sequestration of parasitized
RBCs within the deep vascular beds of many tissues. Here,
the infected cells bind to molecules on the endothelial sur-
face of blood vessels, resulting in obstruction of blood flow
and tissue damage through poorly understood processes. In
nonpregnant individuals for instance, cytoadherence of in-
fected cells within the brain can lead to the potentially lethal
syndrome of cerebral malaria (10). Exposure of PfEMP1 on
the infected cell surface stimulates an antibody response by
the host; however, by switching expression between differ-
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ent 
 
var
 
 genes, parasite populations can undergo antigenic
variation and thus maintain a persistent infection (10). Dif-
ferent parasite strains contain distinct 
 
var
 
 gene repertoires al-
lowing repeated infections with 
 
P. falciparum
 
. These discov-
eries effectively linked both cytoadherence and antigenic
variation to the 
 
var
 
 gene family and led to the hypothesis that
expression of different 
 
var
 
 genes results in different cytoad-
herence phenotypes, in turn leading to sequestration in al-
ternative tissues and ultimately resulting in variable disease
outcomes. This raised the possibility that expression of a spe-
cific 
 
var
 
 gene or subset of 
 
var
 
 genes may be responsible for
CSA binding, cytoadherence in the placenta, and PAM.
Indirect observations suggest the placenta does affect
PfEMP1 protein expression. Since most PfEMP1 proteins
bind the primary microvasculature receptor CD36 (11),
this suggests that the placenta selects for parasites expressing
a non-CD36 binding PfEMP1 protein that ensures local-
ization in placenta instead of within the microvasculature.
Which PfEMP1 proteins are expressed by placental isolates
has been the subject of intense study and current debate. A
variety of approaches, including gene expression, proteo-
mics, CSA binding experiments, and serological investiga-
tion, have provided conflicting evidence regarding whether
a 
 
var
 
 gene called 
 
var1csa
 
 is involved in placental binding
(12–14). Despite questions about its natural role in PAM,
antibodies to 
 
var1csa
 
 recombinant proteins do react with
CSA binding lines, suggesting it has the potential to con-
tribute to a PAM vaccine (15). More recently, a genome-
Figure 1. Binding of infected erythrocytes to microvasculature endothelium versus placenta. Pregnant women, especially first-time pregnant mothers,
are susceptible to massive sequestration of infected erythrocytes in the placenta. Placental isolates are antigenically and functionally distinct from those
found systemically and do not bind the primary microvasculature receptor CD36, but instead bind to CSA. Because CSA-binding parasite variants are
rare in infections before pregnancy, the parasite is able to exploit a gap in malaria immunity to establish high density infections in the placenta. During
pregnancy, women develop antibodies to the infected erythrocyte surface that may either block infected erythrocyte binding or coat them for destruction
by monocytes, thereby reducing disease severity in subsequent pregnancies. Modified with permission from the National Academy of Sciences (Gamain
B., S. Gratepanche, L.H. Miller, and D.I. Baruch. Proc. Natl. Acad. Sci. USA. 2002. 99:10020–10024). 
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wide transcriptional screen identified a distinct 
 
var
 
 gene,
 
var2csa
 
, which was transcriptionally up-regulated in a CSA-
binding parasite line (16). In this issue, Salanti et al. (17)
provide compelling new evidence that the protein encoded
by 
 
var2csa
 
 is actually expressed at the surface of CSA-adher-
ent lines and is an important target of protective antibodies
from pregnant women. Infected pregnant mothers with
higher levels of anti-
 
var2csa
 
 antibodies have a fourfold
lower risk of giving birth to a seriously underweight infant
(17), providing the first direct evidence that protective an-
tibodies recognize a PfEMP1 molecule. Unlike the major-
ity of the 
 
var
 
 gene family, which tends to be extremely
polymorphic and diverse between parasite strains, both
 
var1csa
 
 and 
 
var2csa
 
 have diverged less extensively and are
found within the genomes of most parasite isolates (14).
The prospect that PAM may be mediated by expression of
only one or two relatively conserved 
 
var
 
 genes is indeed
encouraging for vaccine development. As these two anti-
gens are moved forward as vaccine candidates, we are now
confronted with the task of verifying that they do in fact
represent the key molecules responsible for PAM and de-
termining how best to test and ultimately implement a
PAM-specific vaccine.
 
Vaccination Based on Variant Antigens.
 
The concept of a
vaccine based on a variable antigen like PfEMP1 may strike
some as counterintuitive because of the potential for escape
mutants that would evade immunity. For example, if PAM
is determined by a few members of a hyper-variable gene
family like 
 
var
 
, why do parasites not simply mutate these
genes and evade immunity in multigravid women? This
raises the key question of whether we have identified the
optimal PAM vaccine targets in 
 
var1csa
 
 and 
 
var2csa
 
, or
whether placental isolates express other non-PfEMP1 pro-
teins that are more invariant and are the main targets of
protective immunity. This important question is further
complicated by sero-epidemiological investigations that sug-
gest that PAM immunity is acquired only gradually and
may require chronic or multiple placental infections over
more than one pregnancy (18, 19). An additional puzzling
finding is that pregnant women have antibodies that react
with CSA-binding parasites as early as the second trimester
(18, 19), yet are still infected at term. Both observations
could be explained if placental isolates do have some anti-
genic diversity within surface antigens but are not suffi-
ciently divergent to prevent the eventual development of a
broadly protective antibody response (8). These and other
unresolved issues regarding PAM justify a more detailed
look at the current most promising anti-PAM vaccine can-
didates, the proteins encoded by 
 
var1csa
 
 and 
 
var2csa
 
.
As mentioned above, both 
 
var1csa
 
 and 
 
var2csa
 
 are unusu-
ally conserved compared with other members of the 
 
var
 
gene family. Although it might be assumed that this con-
servation simply reflects the shared ability of these proteins
to bind CSA, this does not explain why homologues are
strikingly conserved over their entire extracellular region
and not simply at specific binding domains (16, 20). This is
unexpected because PfEMP1 proteins have multiple bind-
ing domains, whose adhesion properties appear to function
independently (9). It is almost as though the entire extra-
cellular binding region has been simultaneously selected,
perhaps to bind multiple placental receptors (CSA, HA,
and others) or for some other unidentified reason. Also, al-
though the sequence conservation of 
 
var1csa
 
 and 
 
var2csa
 
 is
indeed extreme, compared with most other parasite pro-
teins they are still highly polymorphic. For example, the se-
quences of 
 
var2csa
 
 from different parasite isolates have
 
 
 
80% identity (20). It is possible that these allelic polymor-
phisms could explain why the acquisition of PAM immu-
nity is not more immediate. To inform vaccine design, it
will be imperative to develop a more comprehensive pic-
ture of 
 
var1csa
 
 and 
 
var2csa
 
 sequence conservation both
between different parasite strains and from different geo-
graphical locations. In addition, as long as many details of
PAM remain unresolved it is important to emphasize that
additional work should be done to establish whether pla-
cental infection induces the expression of new parasite pro-
teins at the erythrocyte surface other than those encoded by
 
var1csa
 
 and 
 
var2csa
 
.
 
Toward a PAM Vaccine.
 
With the identification of PAM
vaccine candidates, strategies for testing and evaluating
these antigens will need to be developed. If our intention is
to stimulate the type of immunity naturally acquired by
multigravid women, it is reasonable to question how
well we actually understand PAM immunity. In pregnant
women, antibodies develop that can block infected eryth-
rocyte binding to CSA or simply react with the infected
erythrocyte surface and presumably opsinize them for
uptake by monocytes. Both antibody types increase with
PAM exposure and have been correlated with improved
pregnancy outcomes (21, 22), but it is not yet clear if either
is more important for protection. The fact that HIV infec-
tion impairs the development of humoral immunity to pla-
cental isolates (23) could explain the increased susceptibility
to malaria seen in pregnant women coinfected with HIV,
providing further support for the protective role of anti-
bodies in PAM. Vaccine adjuvants should presumably favor
cytophilic antibody isotypes that will support antibody-
dependent cellular mechanisms of protection, although in
vitro assays to measure antibody-dependent cellular immu-
nity to placental isolates have not been developed.
Options for testing PAM vaccines are currently limited.
Although 
 
P. falciparum
 
 cytoadherence can be studied in the
New World Monkeys species, 
 
Aotus
 
 and 
 
Saimiri
 
 (24), mod-
els for cerebral malaria and pregnancy malaria have not yet
been developed. Work is proceeding, however, on a 
 
P.
coatneyi
 
–rhesus monkey model for pregnancy malaria (25)
that may have some utility. One challenge is that different
 
Plasmodium
 
 species evolved distinct variant antigen families
(25, 26), and significantly only some 
 
Plasmodium
 
 species en-
code strong binding function into the variant genes and are
sequestered (24). Further study of the simian 
 
Plasmodium
 
species could increase our understanding of 
 
var
 
/PfEMP1
protein family evolution and validate these species as mod-
els for human disease. As an example, 
 
P. coatneyi
 
–infected
erythrocytes produce knob-like protrusions at the erythro-
cyte surface that have some similarities to 
 
P. falciparum
 
 and 
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are sequestered from blood circulation like 
 
P. falciparum
 
(25). It will be important to determine whether the genes
and mechanisms responsible for sequestration are con-
served. Primate models, in addition to allowing vaccine
therapeutics to be tested for efficacy, safety, and mecha-
nisms of action, could provide new insights into malaria
pathogenesis from placental or cerebral complications and
the opportunity to study placental binding phenotypes and
antibody development over the course of pregnancy. In the
absence of animal models, clinical testing of 
 
var1csa
 
 and/or
 
var2csa
 
 in women may be just around the corner.
Since the sequences of 
 
var1csa
 
 and 
 
var2csa
 
 vary between
strains, to be efficacious a PAM vaccine will need to stimu-
late a broad antibody response. It is an encouraging sign
that 
 
var2csa
 
 recombinant proteins were recognized by preg-
nant mother sera from both East and West Africa and that
rabbit sera to these recombinant proteins were able to
cross-react with a CSA-binding line from a different strain
(17). How well these antisera recognize different placental
isolates will be the next important test. Several forms of
each antigen may need to be combined in vaccine mixes
that may need to be tailored to particular geographic re-
gions. This will add additional complexity and expense to
the ultimate vaccine cost, since different antigen mixtures,
protein purification processes, or nonprotein-based vaccine
platforms may need to be tested and optimized. The possi-
bility of a PAM vaccine also raises important questions for
deployment. Most significant are the timing and mecha-
nisms by which women could be immunized before their
first pregnancies, especially in Africa where the health in-
frastructure is inadequate. These are important concerns
that will need to be addressed to develop a PAM vaccine
that can protect the health of mother and fetus.
 
Prospects for Syndrome-specific Antimalaria Vaccines.
 
Re-
searchers have strived for decades to develop an effective
vaccine to combat malaria morbidity and mortality. Consid-
ering the variability of malaria surface antigens and the fact
that no subunit vaccine against a parasite or bacterial patho-
gen has ever been successfully developed, the prospect of a
vaccine that can prevent or limit parasite infection is indeed
daunting. However, the study of Salanti et al. (17) and other
recent advances hint that it may be possible to develop vac-
cines that target disease-specific erythrocyte surface variants
rather than infection in general. Similar to PAM, there is
evidence that other disease phenotypes may be associated
with a more limited subset of variant antigens. For instance,
infected erythrocyte antigenic types associated with severe
childhood malaria appear to be more common between
parasite strains than is typical (27). In addition, immunity to
noncerebral, severe malaria infections may be acquired after
one or two infections (28). These observations could be ex-
plained if particular antigenic types were responsible for se-
vere childhood malaria. Indeed, a 
 
var
 
 gene common to dif-
ferent parasite strains was recently associated with severe
childhood malaria (29). Whether it can be established that a
limited and specific subset of PfEMP1 variants cause disease
is still an open question. However, the discovery of strain-
transcendent loci has significant implications for parasite bi-
ology and possibly for human disease and needs to be ex-
plored more fully. With our increasing understanding of the
interactions between host and parasite and the pioneering
studies of PAM, there is renewed hope that antimalaria vac-
cines will finally have an impact on the toll that malaria
takes on the populations of the developing world.
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